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Depression is common after stroke. This substantive update including new and combination 
interventions expands on our previous Cochrane Reviews published in 2004 and updated in 
2008. 
Search methods 
We searched electronic databases from inception to August 2018, clinical trial registers, 
conference proceedings, and contacted study authors. 
Selection criteria 
Randomised controlled trials comparing (1) pharmacological interventions with placebo; (2) 
non-invasive brain stimulation with sham stimulation/usual care; (3) psychological therapy 
with usual care/attention control; (4) pharmacological and psychological therapy with 
pharmacological intervention and usual care/attention control; (5) non-invasive brain 
stimulation and pharmacological intervention with pharmacological intervention and sham 
stimulation/usual care; to treat depression. Four comparisons are not reported because we 
found no trials.  
Results 
49 trials (56 comparisons) with 3342 participants. Data were available for intervention (1) 
with 20 comparisons; (2) with 8; (3) with 16; (4) with 2; and (5) with 10 comparisons.  
We have very little confidence in the following results due to the methodological limitations of 
many of the included trials. 
Pharmacological interventions may decrease the number of people with diagnosable 
depression (RR 0.70, 95% CI 0.55-0.88; 8 trials, 1025 participants, see Figure), and with 
<50% reduction in depression scale scores at end of treatment (RR 0.47, 95% CI 0.32-0.69; 
6 trials, 511 participants) compared to placebo. There was an increase in adverse events 
related to the central nervous system (CNS) (RR 1.55, 95% CI 1.12-2.15; 5 trials, 488 
participants) and gastrointestinal adverse events (RR 1.62, 95% CI 1.19-2.19; 4 trials, 473 
participant) compared to placebo.  
Psychological therapy may decrease the number of people with diagnosable depression at 
end of treatment (RR 0.77, 95% CI 0.62-0.95; 6 trials, 521 participants) with no evidence of 
death or adverse events compared to usual care/attention control.  
There were no trials of non-invasive brain stimulation or combination therapies that reported 
the prevalence of diagnosable depression at end of treatment. Non-invasive brain 
stimulation interventions and combination therapies resulted in no deaths. 
Figure. Effect of pharmacotherapy versus placebo on depression at the end of treatment, 
grouped by method used to determine depression  
Discussion 
We lack confidence in the results for pharmacological and psychological interventions 
showing evidence of benefit and harm. The harm (in pharmacological trials) is concerning 
given the small number of trials in which harm was recorded and reported. 
Large, well-designed trials, with proper collection of adverse events, for moderate/severe 
depression identified by standardised case-finding in the first six months after stroke are 
needed. In the absence of such trials, the best clinical advice is: restrict antidepressant 
prescription to people with persistent depression of moderate-severe intensity, and exercise 
caution in people with a history of falls, fracture or gastrointestinal bleeding. 
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